secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0001193125-25-035162
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene expands collaboration with Foresight for MRD companion diagnostic; commits $37.3M
--------------------------------------------------------------------------------

- Amended agreement covers MRD assay development as companion diagnostic for cema-cel in EU, UK, Canada, Australia.
- Allogene to fund approximately $37.3 million for assay development, milestone payments, and clinical sample testing.
- Parties will use commercially reasonable efforts to obtain regulatory approval for respective products.
- Each party retains ownership of its background IP and improvements; termination rights unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000119312525035162/0001193125-25-035162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000119312525035162/d926019d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-035162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer